8-benzyl-1-(2-hydroxy-ethyl)-3-phenyl-6-propyl-1,4-dihydro-8H-1,2,4a,6,8,9-hexaaza-fluorene-5,7-dione | 905444-27-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 8-benzyl-1-(2-hydroxy-ethyl)-3-phenyl-6-propyl-1,4-dihydro-8H-1,2,4a,6,8,9-hexaaza-fluorene-5,7-dione
• 英文别名: 9-benzyl-1-(2-hydroxyethyl)-3-phenyl-7-propyl-4H-purino[8,7-c][1,2,4]triazine-6,8-dione
• CAS: 905444-27-1
• 化学式: C₂₅H₂₆N₆O₃
• 分子量: 458.52
• InChiKey: DUBPHADYOBNKNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  94.3
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Novel adenosine A3 receptor modulators
  申请人：Baraldi Giovanni Pier

  公开号：US20060178385A1

  公开（公告）日：2006-08-10

  A class of novel antagonists for the adenosine A 3 receptor are disclosed. These compounds are useful as therapeutic agents for a number of diseases and medical conditions that are mediated by the A 3 receptor. The compounds of this invention are also useful as diagnostic agents for the A 3 receptor.

  本发明揭示了一类新型的腺苷A3受体拮抗剂。这些化合物可用作治疗多种由A3受体介导的疾病和医疗状况的治疗剂。本发明的这些化合物还可用作A3受体的诊断试剂。
• METHODS OF TREATING ATHEROSCLEROSIS
  申请人：Leung Edward

  公开号：US20110190324A1

  公开（公告）日：2011-08-04

  The present invention relates to adenosine A3 receptor antagonists and their use for the prevention and treatment of atherosclerosis by administering to a mammal, in need thereof, a therapeutically effective amount of an adenosine A3 receptor antagonist, or a pharmaceutically acceptable salt thereof, alone or in combination with other anti-atherosclerotic agents.

  本发明涉及腺苷A3受体拮抗剂及其在预防和治疗动脉粥样硬化方面的使用，通过向需要的哺乳动物单独或与其他抗动脉粥样硬化药物联合使用，给予治疗有效量的腺苷A3受体拮抗剂或其药学上可接受的盐。
• NOVEL ADENOSINE A3 RECEPTOR MODULATORS
  申请人：King Pharmaceuticals Research and Development Inc.

  公开号：EP1845993A2

  公开（公告）日：2007-10-24
• EP1845993A4
  申请人：——

  公开号：EP1845993A4

  公开（公告）日：2009-03-11
• US7435740B2
  申请人：——

  公开号：US7435740B2

  公开（公告）日：2008-10-14